Compare Robinhood Markets, Inc. (HOOD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Sana Biotechnology Inc — how do they compare? Robinhood Markets, Inc. trades at $101.57 (market cap $89.13B), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: Robinhood Markets, Inc. is far larger — about 102× Sana Biotechnology Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HOOD | SANA | |
|---|---|---|
Market Cap | $89.13B | $873.84M |
Sector | Technology | Health |
52-Week High | $152.46 | $5.92 |
52-Week Low | $65.16 | $2.68 |
Enterprise Value | $90.33B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $99.41, down 0.55% on the day, with technical indicators showing a bearish short-term trend. The stock has strong fundamentals, including 2025 revenue of $4.47 billion and net income of $1.88 billion, with a net margin of 42.09%. Recent news highlights institutional selling and CFO share disposals, but analyst consensus remains bullish with a $113.21 price target. Cash flow improved significantly in 2025 to $1.20 billion net.
The outlook for HOOD is mixed: strong profitability and growth support upside potential, but near-term technical weakness and insider selling pose risks. Investors should weigh robust financials against market sentiment and competitive pressures in the fintech sector.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
